GW Pharma is the clear worldwide leader in cannabis-based pharmaceuticals

  • GW’s pipeline has a number of significant treatments in development for epilepsy, glioma and schizophrenia.
  • Results for its lead candidate Epidiolex in LGS and Dravet syndrome appear quite promising and definitive.
  • The company appears to have an event-filled second half of the year and early 2018 with several opportunities for value creation.

GW Pharma (GWPH) is a regular biotech company that is developing therapies for regular diseases using a very irregular and unusual therapeutic base - cannabinoids. That gives it a clear edge in a sea of fly-by-night mom-and-pop joints which have come up after the United States decided to take a hands-off approach towards the medical and recreational marijuana industry. Many of these other companies have been multibaggers, going up and sometimes down in a frenzy of (marijuana) excitement. However, GWPH is a serious company, and its aim is to discover if there’s any truth behind the millennia-old belief in the medicinal properties of marijuana. At least that is how I look at this investment.

The full unabridged post was first published, and can be accessed, on SeekingAlpha Marketplace.

An abridged version is reproduced below for our investor members. Login or Subscribe here.